216 related articles for article (PubMed ID: 15928663)
1. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
[TBL] [Abstract][Full Text] [Related]
3. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
Grampsas SA; Kahn K; Crawford ED
Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
Uchio EM; Linehan WM; Figg WD; Walther MM
J Urol; 2003 Jan; 169(1):357-60. PubMed ID: 12478189
[TBL] [Abstract][Full Text] [Related]
5. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
van der Heijden AG; Moonen PM; Cornel EB; Vergunst H; de Reijke TM; van Boven E; Barten EJ; Puri R; van Kalken CK; Witjes JA
J Urol; 2006 Oct; 176(4 Pt 1):1349-53; discussion 1353. PubMed ID: 16952629
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.
McKiernan JM; Masson P; Murphy AM; Goetzl M; Olsson CA; Petrylak DP; Desai M; Benson MC
J Clin Oncol; 2006 Jul; 24(19):3075-80. PubMed ID: 16809732
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.
Elsässer-Beile U; Leiber C; Wetterauer U; Bühler P; Wolf P; Lucht M; Mengs U
Anticancer Res; 2005; 25(6C):4733-6. PubMed ID: 16334168
[TBL] [Abstract][Full Text] [Related]
8. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
9. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
10. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
Walther MM; Figg WD; Linehan WM
World J Urol; 1996; 14 Suppl 1():S8-11. PubMed ID: 8738403
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
Elsässer-Beile U; Leiber C; Wolf P; Lucht M; Mengs U; Wetterauer U
J Urol; 2005 Jul; 174(1):76-9. PubMed ID: 15947582
[TBL] [Abstract][Full Text] [Related]
14. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
15. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
16. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.
Hendricksen K; Moonen PM; van der Heijden AG; Molkenboer-Kuenen J; Hulsbergen-van de Kaa CA; Witjes JA
Clin Cancer Res; 2006 Apr; 12(8):2597-601. PubMed ID: 16638871
[TBL] [Abstract][Full Text] [Related]
17. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.
Falke J; Lammers RJ; Arentsen HC; Ravic M; Pozzi R; Cornel EB; Vergunst H; de Reijke TM; Witjes JA
J Urol; 2013 Jun; 189(6):2077-82. PubMed ID: 23206424
[TBL] [Abstract][Full Text] [Related]
18. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.
Jain A; Phillips RM; Scally AJ; Lenaz G; Beer M; Puri R
Urology; 2009 May; 73(5):1083-6. PubMed ID: 19232688
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
Liu B; Wang Z; Chen B; Yu J; Zhang P; Ding Q; Zhang Y
Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
